SHINPOONG PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SHINPOONG PHARMACEUTICAL CO.,LTD's Market Cap is ₩4300B. At end of 2025 it was ₩7827B. Ranked #489 of 2,436 in KR market (top 20%), #306 of 787 on KOSPI (top 39%), #56 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 430.01B KRW | KR#489/2,436 Sec#56/234 |
| Revenue | 233.80B KRW | KR#936/2,436 Sec#52/234 |
| Net Income | 10.01B KRW | KR#902/2,436 Sec#57/234 |
| Total Assets | 371.88B KRW | KR#892/2,436 Sec#53/234 |
| Net Assets | 292.26B KRW | KR#708/2,436 Sec#47/234 |
| Employees | 832 | KR#297/2,436 Sec#24/234 |
| Value | ||
| P/E | 42.94x | KR#1,330/2,436 Sec#85/234 |
| P/B | 1.47x | KR#1,775/2,436 Sec#127/234 |
| P/S | 1.84x | KR#1,778/2,436 Sec#102/234 |
| EV/EBITDA | 27.57x | KR#1,166/2,436 Sec#75/234 |
| FCF Yield | 3.20% | KR#993/2,436 Sec#66/234 |
| Profitability | ||
| ROE | 3.43% | KR#1,183/2,436 Sec#85/234 |
| ROA | 2.69% | KR#1,001/2,436 Sec#84/234 |
| Op. Margin | 6.70% | KR#731/2,436 Sec#61/234 |
| Revenue Growth | -1.59% | KR#1,531/2,436 Sec#147/234 |
| Financial Health | ||
| Debt Ratio | 27.24% | KR#83/2,436 Sec#10/234 |
| Total Debt | 53.81B KRW | KR#959/2,436 Sec#65/234 |
| FCF | 13.78B KRW | KR#620/2,436 Sec#34/234 |
| Cash | 52.15B KRW | KR#732/2,436 Sec#45/234 |
| Current Ratio | 3.20x | KR#567/2,436 Sec#83/234 |
| Net Debt/EBITDA | 0.11x | KR#701/2,436 Sec#45/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -31.63% | KR#1,611/2,436 Sec#139/234 |
| 1M Return | -1.23% | KR#1,023/2,436 Sec#99/234 |
| From 52W High | -49.43% | KR#1,164/2,436 Sec#101/234 |
| 1Y MDD | -55.13% | KR#1,162/2,436 Sec#92/234 |
| Trading | ||
| Volume | 69,591 shares | KR#1,152/2,436 Sec#110/234 |
| Foreign Own. | 6.41% | KR#677/2,436 Sec#66/234 |
| Per Share | ||
| EPS | 190 KRW | KR#1,217/2,436 Sec#86/234 |
| BPS | 5,507 KRW | KR#1,370/2,436 Sec#99/234 |
Company Info
Established in 1962 and listed on the Korea Exchange in 1990, the company is a mid-sized pharmaceutical enterprise primarily focusing on the manufacturing and sale of finished pharmaceutical products and active pharmaceutical ingredients. It operates six subsidiaries for overseas market entry in countries like Vietnam, Philippines, Myanmar, and the United States. The company concentrates its mid-to-long-term capabilities on global new drug development and secures domestic market competitiveness by launching improved new drugs and first generics, and fostering highly profitable items into mega-products.